Human papillomavirus infection

The BioInnovation Institute welcomes eight new companies to its Venture Lab program

Retrieved on: 
Thursday, August 31, 2023
Laboratory, Lead poisoning, Novozymes, Cancer, Research, Immunotherapy, Wilson, Wilson's disease, EUR, Dysplasia, Patient, Corporation, HPV, Knowledge, Diagnosis, BII, Therapy, Human papillomavirus infection, Pharmaceutical industry, Medical imaging

COPENHAGEN, Denmark, Aug. 31, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that eight new companies have entered its Venture Lab acceleration program for early-stage companies.

Key Points: 
  • COPENHAGEN, Denmark, Aug. 31, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that eight new companies have entered its Venture Lab acceleration program for early-stage companies.
  • In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII's Venture House program.
  • Bobby Soni, Chief Business Officer at BioInnovation Institute, said: "These eight early-stage companies are a fantastic addition to BII's Venture Lab.
  • The new companies BII has accepted into the Venture Lab acceleration program are:
    Loma Therapeutics is developing targeted immunotherapy for efficient and safe treatment of patients with HPV infection, dysplasia, and cancer.

The BioInnovation Institute welcomes eight new companies to its Venture Lab program

Retrieved on: 
Thursday, August 31, 2023
Laboratory, Lead poisoning, Novozymes, Cancer, Research, Immunotherapy, Wilson, Wilson's disease, EUR, Dysplasia, Patient, Corporation, HPV, Knowledge, Diagnosis, BII, Therapy, Human papillomavirus infection, Pharmaceutical industry, Medical imaging

COPENHAGEN, Denmark, Aug. 31, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that eight new companies have entered its Venture Lab acceleration program for early-stage companies.

Key Points: 
  • COPENHAGEN, Denmark, Aug. 31, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that eight new companies have entered its Venture Lab acceleration program for early-stage companies.
  • In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII's Venture House program.
  • Bobby Soni, Chief Business Officer at BioInnovation Institute, said: "These eight early-stage companies are a fantastic addition to BII's Venture Lab.
  • The new companies BII has accepted into the Venture Lab acceleration program are:
    Loma Therapeutics is developing targeted immunotherapy for efficient and safe treatment of patients with HPV infection, dysplasia, and cancer.

Hybribio showcased cutting-edge cervical cancer HPV diagnostic solutions at ADLM 2023

Retrieved on: 
Monday, July 31, 2023
SOX1, Anaheim Convention Center, CE, ASC, Urinary tract infection, Fluorescence, AACC, Human papillomavirus infection, Mass spectrometry, Movement, ASC-US, Ministry, Hospital, Triage, Cervical cancer, Child, MEDICA, HPV, WHO, Health, Methylation, PCR, Vaccine

At the booth No.1482, Hybribio (300639.SZ) featured cervical cancer HPV diagnostic solutions, which include Hybribio 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, 14 High-Risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), and SOX1 and PAX1 Methylation Real-time PCR Kit.

Key Points: 
  • At the booth No.1482, Hybribio (300639.SZ) featured cervical cancer HPV diagnostic solutions, which include Hybribio 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, 14 High-Risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), and SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Being the top HPV DNA test manufacturer in China, Hybribio (300639.SZ) not only has the biggest Chinese market share (over 40%) of HPV testing kits but also contributes greatly to the movement of eliminating cervical cancer.
  • Hybribio (300639.SZ) is going to attend MEDICA 2023 at Dusseldorf, Germany, 13-16 November 2023.
  • Hybribio is looking forward to meeting you in person at MEDICA 2023, where Hybribio will feature more cutting-edge diagnostics solutions and high-throughput automated instruments.

New Research Shows Promising Possibilities for At-Home Testing to Detect Sexually Transmitted Infections

Retrieved on: 
Tuesday, July 25, 2023
Vagina, Laboratory, Kaiser Permanente, Human papillomavirus infection, STI, Urine, Infection, Los Angeles County Department of Health Services, Research, Temperature, Neisseria gonorrhoeae, Doctor of Philosophy, Centers for Disease Control and Prevention, Chlamydia trachomatis, Public health, Rectum, Cervical cancer, Los Angeles County Department of Public Health, Physician, HPV, Patient, Throat, Birth control, Mineral oil, Neisseria, Chlamydia

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo. These findings could enable discreet new testing options that expand access to screening.

Key Points: 
  • ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo.
  • However, more research is needed to establish the reliability of self-collected tests.
  • For 15 study participants, the researchers evaluated 5 self-collected swabs to assess variability in swabs taken from the same individual.
  • The researchers were motivated to increase inclusivity and access to STI testing by exploring additional options for self-collection and home testing.

Cervical Intraepithelial Neoplasia Drug Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & Dohme - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 20, 2023
Health, Pharmaceutical, CIN, Artesunate, Society, Therapy, Clinical trial, NDA, Woman, Society of Gynecologic Oncology, Cervical intraepithelial neoplasia, Research, Candidiasis, E7, Discovery, E6, Gynaecology, HPV, Growth, Intraepithelial neoplasia, III, Inovio Pharmaceuticals, Human papillomavirus infection, News, Birth control, Pharmaceutical industry, Gynecologic Oncology (journal), Cervical, Phase

The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report report offers a comprehensive analysis of the current landscape and future growth prospects in the field of Cervical Intraepithelial Neoplasia.
  • This report provides a detailed overview of the pipeline for Cervical Intraepithelial Neoplasia, including profiles of over 8 companies and 10 pipeline drugs.
  • The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e.

Microbix QAPs Supporting HPV Testing Across The Netherlands

Retrieved on: 
Wednesday, July 5, 2023
Human papillomavirus infection, BVO, Workflow, Infection, Woman, QAP (Colombia), Cervical cancer, Laboratory, Immune system, Cancer, OTCQX, HPV, MDX, TSX, BD, Vaccine, EU

The program is being driven by the instrumentation and reagents of the BD COR™ system and its Onclarity™ HPV assay.

Key Points: 
  • The program is being driven by the instrumentation and reagents of the BD COR™ system and its Onclarity™ HPV assay.
  • Microbix REDx® liquid-format IVD-regulated QAPs will be used to support the quality management system monitoring the ongoing accuracy of laboratory performance for the program.
  • Rob Schuurman, National Reference Officer for the Dutch Cervical Cancer Screening Program (BVO), noted “MDx testing for HPV improves cervical cancer screening by identifying those at-risk efficiently.
  • Close monitoring of the entire HPV testing workflow is critical to realizing this healthcare goal and Microbix’s HPV QAPs have been selected to support the quality assessment monitoring of the molecular testing process, a vital part of BVO’s quality management system.”

Genexine Abstract on GX-188E and GX-I7 Triple Combination Therapy in HNSCC Is Released at 2023 ASCO Annual Meeting

Retrieved on: 
Friday, May 26, 2023
Research, Pharmaceutical, Oncology, Consumer, Technology, Artificial Intelligence, Genetics, Clinical Trials, Science, Women, Biotechnology, Health, Survival rate, DNA, IIT, MPR, Neoadjuvant therapy, TIL, Neoplasm, Clinical trial, Quality of life, Head, Immunotherapy, PCR, Severance Hospital, Trial of the century, ASCO, Professor, American Society of Clinical Oncology, Patient, Cervical cancer, Division, Annual general meeting, HNSCC, HPV, Pembrolizumab, Smoking, Tumor microenvironment, Society, Human papillomavirus infection, Cancer, Safety, Pharmaceutical industry, Medical imaging

The study evaluated the DNA vaccine GX-188E (tirvalimogene teraplasmid) and the lymphopenia-correcting immune-oncology drug GX-I7 (efineptakin alfa) in combination with immune checkpoint inhibitor Keytruda® (pembrolizumab).

Key Points: 
  • The study evaluated the DNA vaccine GX-188E (tirvalimogene teraplasmid) and the lymphopenia-correcting immune-oncology drug GX-I7 (efineptakin alfa) in combination with immune checkpoint inhibitor Keytruda® (pembrolizumab).
  • The primary endpoint evaluated the major pathological response (MPR) and other evaluation criteria included safety, recurrence rate and survival rate.
  • All 11 patients who participated in the trial underwent surgery as planned after neoadjuvant therapy with no increase in surgical delay or surgical complications.
  • The results of this study will be presented in a poster session at the ASCO 2023 Annual Meeting, which will be held in Chicago from June 2 to 6, 2023.

COMPASSIONATE CERVIX BRUSH BIOPSY DEVICES PIVOTAL FOR NCI GLOBAL "MOONSHOT" CANCER SCREENING INITIATIVE

Retrieved on: 
Tuesday, May 16, 2023
Infection, Human papillomavirus infection, Histology, Obstetrics, HIV, University of California, Irvine School of Medicine, Initiative, PAVE, Cervical cancer, Cancer, Multimedia, National Cancer Institute, Cervical, UC, Patient, Physician, Nursing, Control, Gynaecology, Gynecologic oncology, MPH, NCI, Safety, Biopsy, Birth control, Medical imaging, Medicine

ANAHEIM, Calif., May 16, 2023 /PRNewswire/ -- Histologics LLC manufactures Kylon® medical fabric sterile brush devices which use gentle friction to biopsy the outer cervix and endocervical canal.

Key Points: 
  • ANAHEIM, Calif., May 16, 2023 /PRNewswire/ -- Histologics LLC manufactures Kylon® medical fabric sterile brush devices which use gentle friction to biopsy the outer cervix and endocervical canal.
  • Over 1 million of such cervical biopsies have been performed with this technology in the USA.
  • "Clinicians want to find true cervical cancer precursors at an early treatable stage, known to be caused by infection with the Human Papilloma Virus".
  • "The histology results obtained with the Histologics' biopsy devices have been diagnostic from samples thus far in Cambodia and a cervical cancer has been already diagnosed" said Dr. Goldstein.

Northwell Health Commits $1M to Fund Employee Ideas for Healthcare Innovation During Big Ideas Showcase

Retrieved on: 
Monday, May 8, 2023
Hospitals, General Health, Health, Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Endometriosis, Hofstra University, Donald, Brain, LAUNCH (Innovation Challenge), Culture, Feinstein Institutes for Medical Research, Stroke, DRS, Innovation, MBA, Research, Multimedia, Doctor of Philosophy, Science, Creativity, Trigeminal nerve, North Shore University Hospital, National Institute of Neurological Disorders and Stroke, Neurosurgery, Patient, Nature, HPV, Neurology, Navigation, White, Human papillomavirus infection, Medical research, Nursing, Pharmaceutical industry, Management, Medical imaging, Medical device, Northwell Health, Cancer, MD

Northwell Health has awarded $1 million toward the research and development of two employee-driven projects that drive the goal of transforming the future of health care with new ideas during the health system’s 2023 Innovation Challenge.

Key Points: 
  • Northwell Health has awarded $1 million toward the research and development of two employee-driven projects that drive the goal of transforming the future of health care with new ideas during the health system’s 2023 Innovation Challenge.
  • Winners of the competition included team leads hailing from the Feinstein Institutes for Medical Research , the home of research at Northwell Health.
  • The announcement was made during the health system’s Made for Big Ideas™ Showcase.
  • To date, Northwell has awarded funding for 13 projects to advance their progress and develop their innovative ideas.

Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO

Retrieved on: 
Thursday, April 27, 2023
Vaccine, CIN, Therapy, Virology, GV, 1994 expanded World Health Organization AIDS case definition, Cancer, Woman, Global health, Gilead, Human papillomavirus infection, Acquisition, Cervical cancer, Patient, SAN, Apoptosis, HPV, Knowledge, Diagnosis, Indoleamine 2,3-dioxygenase, Soteria, Health, MPM, Forty-seven rōnin, Pharmaceutical industry, Management

SOUTH SAN FRANCISCO, April 27, 2023 /PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $53 million Series E equity financing. The financing was supported by a syndicate of premier life science investors led by MPM-BioImpact Capital, and joined by the company's existing investors including Canaan Partners, Sofinnova Investments, Adjuvant Capital, GV and Lumira Ventures, among others. In conjunction with the financing, president and chief executive officer Gail Maderis is transitioning to chairman of the company's board of directors and is being succeeded as CEO by Kristine Ball. Additionally, Ms. Ball, along with Florencia Segal, M.D., and Brian Goodman, Ph.D., both of MPM-BioImpact Capital, will join the Antiva board.

Key Points: 
  • The financing was supported by a syndicate of premier life science investors led by MPM-BioImpact Capital, and joined by the company's existing investors including Canaan Partners, Sofinnova Investments, Adjuvant Capital, GV and Lumira Ventures, among others.
  • In conjunction with the financing, president and chief executive officer Gail Maderis is transitioning to chairman of the company's board of directors and is being succeeded as CEO by Kristine Ball.
  • Additionally, Ms. Ball, along with Florencia Segal, M.D., and Brian Goodman, Ph.D., both of MPM-BioImpact Capital, will join the Antiva board.
  • "I take great pride in turning the CEO role over to Kristine with the company in such a strong position following this transformative financing.